- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- LOU064 25 mg (b.i.d), Placebo, LOU064 25 mg (b.i.d) as a tablet.
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 470 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • Bakersfield, California + 23 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 60
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Oral EP262, Placebo
- Drug
- Lead sponsor
- Escient Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 29 more
- Conditions
- Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
- Interventions
- Remibrutinib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- North Miami Beach, Florida • Glenview, Illinois
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Benralizumab, Placebo and Benralizumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- EVO756, Placebo control
- Drug
- Lead sponsor
- Evommune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Fremont, California + 38 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Dupilumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Chronic Spontaneous Urticaria (CSU)
- Interventions
- Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 132
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 104 more
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- Placebo, Omalizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 36
- States / cities
- La Jolla, California • Los Angeles, California • Redwood City, California + 31 more
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- AZD1981, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- barzolvolimab, Matching Placebo
- Biological · Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more
- Conditions
- Chronic Idiopathic Urticaria
- Interventions
- Omalizumab, Placebo, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 40
- States / cities
- Scottsdale, Arizona • Mission Viejo, California • Napa, California + 35 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- LOU064
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Aventura, Florida • Greenacres City, Florida + 7 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- QGE031, Omalizumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 22 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 12 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Kirksville, Missouri
- Conditions
- Healthy Participants, Chronic Spontaneous Urticaria
- Interventions
- AK006-IV, Placebo-IV, AK006-SC, Placebo-SC
- Drug
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- barzolvolimab, Standard of Care
- Biological · Other
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 32 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3, LOU064 Arm 4, LOU064 Arm 5, LOU064 Arm 6, Placebo arm
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 11
- States / cities
- Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 8 more
- Conditions
- Urticaria
- Interventions
- GDC-0853
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 7 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- barzolvolimab, Matching placebo
- Biological
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 963 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Inglewood, California + 50 more
- Conditions
- Chronic Urticaria
- Interventions
- TEV-45779, XOLAIR® Injection
- Combination Product
- Lead sponsor
- Teva Pharmaceuticals USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Bakersfield, California • Clearwater, Florida • Coral Gables, Florida + 6 more
- Conditions
- Urticaria Chronic
- Interventions
- Placebo, 0.5 mg epinephrine, 1 mg epinephrine
- Drug
- Lead sponsor
- ARS Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Glenview, Illinois • Cincinnati, Ohio
- Conditions
- Chronic Urticaria, Idiopathic
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Lirentelimab (AK002), Placebo
- Drug · Other
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 44 more